Allergan's most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $148.00 short call and a strike $155.00 long call offers a potential 12.72% return on risk over the next 7 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $148.00 by expiration. The full premium credit of $0.79 would be kept by the premium seller. The risk of $6.21 would be incurred if the stock rose above the $155.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Allergan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.
The RSI indicator is at 31.74 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
6 Days Left To Allergan plc (NYSE:AGN)’s Ex-Dividend Date, Is It Worth Buying?
Thu, 10 May 2018 00:43:23 +0000
Shares of Allergan plc (NYSE:AGN) will begin trading ex-dividend in 6 days. To qualify for the dividend check of $0.72 per share, investors must have owned the shares prior toRead More…
Musk Meltdown Underscores Art of Keeping Earnings Calls Dull
Wed, 09 May 2018 15:59:12 +0000
From the tedious disclaimers at the outset about “forward-looking statements,” to the desiccated remarks read by leaden financial officers, to the mealy mouthed questions posed by unctuous analysts, the calls tend to emit a tonal range so monotonous that you can listen to hundreds of the proceedings without hearing a single memorable thing. Elon Musk’s recent unruly performance during Tesla’s earnings call — where he bizarrely chastised analysts, telling them among things that “boring, bonehead questions are not cool” — was a reminder of just how seldomly these rituals of corporate pageantry go off the rails. “You never want to see your management representatives fly off the handle with investors,” said Christopher King, vice president of investor relations at Windstream Holdings Inc., which provides telecom services in rural areas.
How Companies Keep Most Earnings Calls So Incredibly Boring
Wed, 09 May 2018 15:59:12 +0000
From the tedious disclaimers at the outset about “forward-looking statements,” to the desiccated remarks read by leaden financial officers, to the mealy mouthed questions posed by unctuous analysts, the calls tend to emit a tonal range so monotonous that you can listen to hundreds of the proceedings without hearing a single memorable thing. Elon Musk’s recent unruly performance during Tesla’s earnings call — where he bizarrely chastised analysts, telling them among things that “boring, bonehead questions are not cool” — was a reminder of just how seldomly these rituals of corporate pageantry go off the rails.
Morgan Stanley Turns Bearish On Ironwood Pharma, Lowers Linzess Sales Estimate
Wed, 09 May 2018 14:13:28 +0000
Commercial stage biopharma company Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD )'s Linzess, which it markets along with Allergan plc (NYSE: AGN ) in the U.S., is a major revenue earner for the company. …
How $6 billion generic drug company merger could affect this East Bay city and Roche
Wed, 09 May 2018 12:57:20 +0000
The headquarters of the combined company is the East Coast, not the East Bay, but Hayward could see more manufacturing work.
Related Posts
Also on Market Tamer…
Follow Us on Facebook